Prevalence, patient characteristics and treatment patterns among systemic lupus erythematosus–pulmonary arterial hypertension patients in real-world clinical practice: A retrospective analysis of Medical Data Vision Database in Japan
Modern Rheumatology · 06.07.2024 · 34 (4) · 741-749
DOI: 10.1093/mr/road090 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Rheumatology, online erschienen am 25.09.2023. Verfasst von Tatsuya Atsumi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Hokkaido, Japan. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Objectives
Real-world evidence regarding prevalence, patient characteristics, and treatment patterns for pulmonary arterial hypertension (PAH) related to systemic lupus erythematosus (SLE) in Japan is limited.
Methods
We conducted a retrospective study analysing Japan’s Medical Data Vision database from April 2008 to September 2020. Prevalence, incidence, patient characteristics, treatment patterns, and use of vasodilators by treatment line were evaluated.
Results
The prevalence of PAH was 0.392% in SLE patients (n = 114/29,077). Cumulative incidence was 0.53% (3 years) and 0.77% (5 years). Of 114 SLE–PAH patients, 49% developed PAH <1 year from SLE diagnosis. SLE–PAH patients were predominantly females (88% vs. 72%), had a lower mean age at SLE diagnosis (53 vs. 56 years), and had more severe SLE (61% vs. 25%) than non-PAH–SLE patients. Glucocorticoids (58%) and vasodilators (27%) were preferred first-line monotherapy for SLE–PAH. A combination of glucocorticoids and immunosuppressants (19%) was the predominant first-line combination therapy. Endothelin receptor antagonists (40% and 44%) and nitric oxide analogues (31% and 40%) were dominant first- and second-line vasodilators.
Conclusions
SLE–PAH patients were predominantly females, were younger at diagnosis, and had more severe SLE than non-PAH–SLE patients. Most were diagnosed <1 year of SLE diagnosis. In Japan’s real-world practice, the initial treatment goal is SLE management, while vasodilators are preferred in advanced diseases, as per the Medical Data Vision database.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Hokkaido, Japan.
- Janssen Pharmaceutical Asia Pacific, Singapore.
- Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore.
- Prospection Pty Ltd, Sydney, NSW, Australia.
- Prospection KK, Tokyo, Japan.
Zitieren
APA
Atsumi, T., Tan, J. Y., Chiang, A. P., Yu, D. Y., Makanji, Y., Wu, D. B., Casorso, J., Kouhkamari, M., & Lim, S. (2024). Prevalence, patient characteristics and treatment patterns among systemic lupus erythematosus–pulmonary arterial hypertension patients in real-world clinical practice: A retrospective analysis of Medical Data Vision Database in Japan. Modern Rheumatology, 34(4), 741-749. https://doi.org/10.1093/mr/road090
Vancouver
Atsumi T, Tan JY, Chiang AP, Yu DY, Makanji Y, Wu DB, et al. Prevalence, patient characteristics and treatment patterns among systemic lupus erythematosus–pulmonary arterial hypertension patients in real-world clinical practice: A retrospective analysis of Medical Data Vision Database in Japan. Modern Rheumatology. 2024;34(4):741-749. doi:10.1093/mr/road090
BibTeX
@article{Atsumi2024,
author = {Atsumi, Tatsuya and Tan, Jin Yu and Chiang, Ashley Pei-Chun and Yu, Dae Young and Makanji, Yogeshwar and Wu, David Bin-Chia and Casorso, Jeremy and Kouhkamari, Mahsa and Lim, Sooyeol},
title = {Prevalence, patient characteristics and treatment patterns among systemic lupus erythematosus–pulmonary arterial hypertension patients in real-world clinical practice: A retrospective analysis of Medical Data Vision Database in Japan},
journal = {Modern Rheumatology},
year = {2024},
volume = {34},
number = {4},
pages = {741--749},
doi = {10.1093/mr/road090}
}
EUVIMED